Remus Pharmaceuticals Q2 FY27 results: net profit up 14.2% to ₹24.66 crore, revenue up 53.5%

How did Remus Pharmaceuticals perform in Q2 FY27?

Remus Pharmaceuticals reported consolidated revenue of ₹614.12 crore for Q2 FY27, up 53.5% from ₹400.20 crore in Q2 FY26. EBITDA was ₹29.93 crore, up 11.2%, while the margin declined 1.8 percentage points to 4.9%.

Profit before tax rose 13.9% to ₹31.77 crore and net profit increased 14.2% to ₹24.66 crore. Profit attributable to owners was ₹21.76 crore, up 24.3%, and basic EPS rose 14.1% to ₹20.92 from ₹18.33.

On a standalone basis, Q2 FY27 revenue was ₹62.08 crore and profit after tax was ₹18.81 crore. No previous-quarter consolidated figures were provided, so a comparison with the immediately preceding quarter cannot be made from the available data.

What changed in Remus Pharmaceuticals' costs and profit?

Total expenses rose 56.3% to ₹586.49 crore from ₹375.23 crore in Q2 FY26, exceeding the 53.5% increase in revenue. Employee cost increased 28.9% by ₹1.80 crore to ₹8.02 crore, while other expenses rose 24.0% by ₹4.20 crore to ₹21.73 crore.

Finance costs rose by ₹0.11 crore to ₹0.76 crore and depreciation increased by ₹0.25 crore to ₹1.54 crore. Cost of materials was unchanged at ₹0 crore, and there was no exceptional item in either quarter.

Other income increased by ₹1.21 crore to ₹4.14 crore from ₹2.93 crore. Tax expense rose by ₹0.80 crore to ₹7.11 crore, while profit before tax increased by ₹3.87 crore to ₹31.77 crore. The net profit margin fell 1.4 percentage points to 4.0% from 5.4%.

Management said SP’s $12 million of low-margin orders increased revenue but diluted consolidated EBITDA and PAT. No filing explanation was provided for the movement in each other expense line.

What do the balance sheet and cash flow show?

At 30 September 2026, total assets were ₹787.59 crore, up from ₹578.65 crore at 31 March 2026, while total equity rose to ₹577.12 crore from ₹387.73 crore. Borrowings declined to ₹21.95 crore from ₹23.04 crore and cash fell to ₹10.02 crore from ₹11.82 crore.

Inventories increased to ₹74.52 crore from ₹72.06 crore. Trade receivables declined to ₹131.78 crore from ₹139.84 crore, while trade payables fell to ₹74.05 crore from ₹76.04 crore.

For H1 FY27, operating cash flow was ₹7.56 crore, compared with ₹9.74 crore in H1 FY26. Investing cash flow was negative ₹7.00 crore against negative ₹2.68 crore, while financing cash flow was negative ₹2.36 crore against negative ₹7.62 crore; capital expenditure was ₹0 crore compared with ₹3.31 crore.

What else did the company announce?

The board approved the unaudited standalone and consolidated financial results for the half year ended 30 September 2026, along with the limited review reports of the statutory auditors. It also approved the first interim dividend of Re.1.00 per equity share of face value ₹10 for FY27.

The board fixed 7 November 2026 as the record date for the first interim dividend, and the company said payment would be made within the timelines prescribed under the Companies Act, 2013. The company also filed its H1 FY27 investor presentation, which reported H1 revenue growth of 53% and a lower EBITDA margin.

No fund-raising or appointment announcement is included in the available same-day filings.

What did Remus Pharmaceuticals' management say?

Management expects H2 FY27 standalone revenue growth to match or exceed H1 FY27, supported by current order bookings. Arpit Shah, Managing Director of Remus Pharmaceuticals, said, “H2 is going to be better than H1.” The company plans to commercialise approved semaglutide tablets and injections in eligible international markets during H2 FY27, with launch countries to be announced later.

Management said the global regulatory portfolio reached 2,443 registrations and applications across more than 40 countries. It plans to file 60 products in Peru, with approvals expected in 4–6 months and commercialisation probably during H2 FY27.

Management stated a long-term margin goal of 5–7% for SP Global. Shah said, “So long term, we think that five to seven percent margins on SP will be there.” Management also expects remaining regulatory and exchange-compliance requirements for main-board migration to close before Diwali, or by end-November 2026.

Management identified risks including dilution from SP’s high-volume, low-margin distribution mix, spending requirements for B2C expansion, dependence of semaglutide commercialisation on patent status and market approvals, and a break-even period of approximately 1.5–3 years for new country subsidiaries. The company said no unpublished price-sensitive information was shared during the earnings call.

How did Remus Pharmaceuticals shares react?

The results were filed after market hours on 3 November 2026. The stock moved from a pre-results close of ₹844.20 to a base price of ₹840.05 after the filing, and remained unchanged at the 5-minute, 15-minute and 30-minute intervals. On the reaction day, the stock fell 3.4% from the pre-results close.

No one-day or five-day cumulative reaction, industry-median move, Nifty Microcap 250 move, or earlier results-day reaction was provided, so relative performance and subsequent session performance cannot be stated from the available data.